Compare Amgen, Inc. (AMGN) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Oatly Group AB - ADR — how do they compare? Amgen, Inc. trades at $417.4 (market cap $224.14B), while Oatly Group AB - ADR trades at $13.18 (market cap $415.98M). The key difference: Amgen, Inc. is far larger — about 538.8× Oatly Group AB - ADR's market cap, and Amgen, Inc. pays a 2.43% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| AMGN | OTLY | |
|---|---|---|
Market Cap | $224.14B | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $417.20 | $18.54 |
52-Week Low | $271.18 | $8.03 |
Enterprise Value | $267.45B | $920.39M |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
OTLY trades at $13.12, down 4.37% today, but maintains a bullish technical outlook with strong moving average and oscillator signals. The company reported Q2 2026 revenue growth and raised full-year guidance, showing progress toward profitability with improving gross margins. However, negative net income and cash flow challenges persist, with the stock trading at a low P/S ratio of 0.44 but elevated P/B of 79.9.
The investment case hinges on OTLY's operational turnaround and revenue acceleration, but significant risks remain from cash burn and high debt levels. Analyst sentiment is mixed with 44% buy ratings, while technical indicators suggest near-term support at $13. The path to sustainable profitability remains the key catalyst for stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
